https://www.selleckchem.com/pr....oducts/ll37-human.ht
failed to demonstrate efficacy of Edaravone to delay the progression of ALS. While the primary desired endpoint was not achieved but there was small improvement in SF-EMG jitter difference of the patients that was not significant statistically. We consider that the study with large sample size results can be helpful to identify the patient population in which Edaravone could be expected to show efficacy. This study failed to demonstrate efficacy of Edaravone to delay the progression of ALS. While the primary desired endpoint was not
Like
Comment
Share
